Ultimovacs has an extensive development program with five phase II studies in five different indications including more than 670 patients:
INITIUM – Malignant melanoma
INITIUM is an Ultimovacs-sponsored randomized, comparative, multicenter Phase II trial in which the universal cancer vaccine, UV1, will be evaluated in combination with the checkpoint inhibitors ipilimumab and nivolumab for first-line treatment of patients with metastatic malignant melanoma.
The first INITIUM patient was treated at the Oslo University Hospital (OUS) in June 2020, and the last patient was enrolled in the study in July 2022. The initial study design called for enrollment of 154 patients. Two additional patients were enrolled bringing the total number of patients in the study to 156. A total of 39 hospitals are participating in this trial being run in the U.S., UK, Belgium and Norway. Dr. Karl Lewis, University of Colorado Hospital (U.S.), is the International Coordinating Investigator of the INITIUM trial.
Half the 156 patients enrolled in the trial have been dosed with UV1 plus the PD-1 checkpoint inhibitor nivolumab and the CTLA-4 checkpoint inhibitor ipilimumab, while the other half received nivolumab and ipilimumab. The readout of the primary endpoint of progression-free survival is expected in H2 2023, after progression of cancer or death has been observed in 70 patients.
Secondary study endpoints will include overall survival (OS), objective response rate (ORR), duration of response (DOR) and safety. The objective of the study is to achieve a clinically meaningful progression-free survival (PFS) benefit in patients with metastatic malignant melanoma.
With the INITIUM enrollment completed, Ultimovacs is running a supplementary study to the INITIUM trial with 20 patients in a single-arm study. Patient enrollment in the supplementary study started in September 2022. The objective of the study is to provide further characterization of the manner in which an immune response specific to the UV1 vaccine translates into anti-tumor activity and clinical benefit for patients. All patients will receive experimental treatment, i.e. the triple combination of UV1, ipilimumab and nivolumab. Data collected from the supplementary study will not be part of the primary and secondary endpoint analyses of INITIUM and will not affect the timeline for topline read-out.
Malignant melanoma is a type of skin cancer that develops when melanocytes (the cells that give the skin its tan or brown color) start to grow out of control. Malignant melanoma is less common than other types of skin cancers, but more dangerous because it is much more likely to spread to other parts of the body if not diagnosed and treated at an early stage. Malignant melanoma can develop anywhere on the skin, but it is more likely to start on the trunk (chest and back) in men and on the legs in women. The neck and face are other common sites.
NIPU – Mesothelioma
NIPU is a randomized, multi-center Phase II trial that assesses the universal cancer vaccine, UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab as second-line treatment in metastatic malignant mesothelioma. The study was designed to assess the impact of UV1 on progression-free survival (PFS) in patients with metastatic pleural mesothelioma after progression on first-line standard platinum doublet chemotherapy. Prof. MD PhD Åslaug Helland is the principal investigator for the trial, which was sponsored by Oslo University Hospital (OUS). Bristol-Myers Squibb and Ultimovacs each entered into agreements with OUS to support the preparations and execution of the trial.
Topline results were reported on June 7, 2023. The results were reported once the required observations of progression of cancer or death were recorded in 69 patients. Secondary endpoints include overall survival (OS), objective response rate (ORR), duration of response (DOR) and safety. Full analysis of the study is underway and expected to be shared in a peer-reviewed setting in the coming months.
The first patient in the NIPU trial was treated at the Oslo University Hospital in June 2020, and the last patient was enrolled in January 2023. The study was conducted in 118 patients in five countries (Norway, Sweden, Denmark, Spain, and Australia). Half of the patients in the trial were treated with the combination of UV1, ipilimumab and nivolumab and the other half with ipilimumab and nivolumab.
MPM is a rare malignant tumor originating from the cells lining the mesothelial surface in the lungs. MPM is the most common type of mesothelioma and is a disease with a high unmet medical need with a median overall survival of approximately one year. Most patients are treated with palliative chemotherapy. Patients with disease progression after first-line therapy have few therapeutic options. Asbestos exposure is heavily linked to the development of the disease. It may take 10 – 50 years for symptoms of mesothelioma to manifest after initial asbestos exposure. Even though the use of asbestos to a large extent is banned today, new incidences of mesothelioma will continue to be a medical challenge for decades.
DOVACC – Ovarian cancer
The trial is designed to evaluate Ultimovacs’ proprietary UV1 cancer vaccine in combination with AstraZeneca’s durvalumab, a PD-L1 checkpoint inhibitor and its PARP inhibitor, olaparib, the maintenance therapy for BRCA-mutated, advanced ovarian cancer. The trial will be conducted at more than 40 hospitals in as many as 10 European countries. The first patient was enrolled in December 2021. Top line data on the primary endpoint has been expected in H2 2024. Ultimovacs will review the guidance and expects to give an update with the Q4 2023 report.
The second-line maintenance study will enroll patients with high-grade BRCA-negative ovarian cancer after partial or complete response following the second round of chemotherapy. The study includes three arms treating a total of 184 patients. The first arm will enroll 46 patients receiving the PARP inhibitor olaparib. The 46 patients enrolled in the second arm will receive olaparib and the checkpoint inhibitor durvalumab. The third arm will include 92 patients that will receive Ultimovacs’ UV1 vaccine in combination with both AstraZeneca drugs. The primary endpoint is progression-free survival (PFS) in the treatment arm with PARP inhibitor olaparib monotherapy, versus PFS in the triple combination treatment arm. Under the terms of the collaboration, Ultimovacs will provide its UV1 vaccine and AstraZeneca will provide the PD-L1 and PARP inhibitors for the study.
DOVACC (Durvalumab Olaparib VACCine) is a multi-center, multinational, randomized Phase II clinical collaboration trial with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU), the European Network of Gynaecological Oncological Trial Groups (ENGOT) and AstraZeneca. The trial is sponsored by the NSGO, the leading gynaecological oncology research society in the Nordic and Baltic regions.
FOCUS – Head and Neck cancer
The FOCUS trial (First-line metastatic Or recurrent HNSCC/Checkpoint inhibitor UV1 Study) is an investigator-sponsored, randomized Phase II clinical trial that will recruit patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma. The trial will be conducted at 10 sites across Germany and led by principal investigator Prof. Mascha Binder, M.D., Medical Director and Head of the Immunological Tumor Group at University Medicine Halle, Germany, who is a renowned oncology clinician and researcher specializing in the analysis of immuno-oncology treatments and their interaction with tumor tissues.
The trial will evaluate the addition of UV1 to a standard of care treatment with PD-1 checkpoint inhibitor pembrolizumab as compared to pembrolizumab monotherapy. A total of 75 patients indicated for treatment with pembrolizumab will be enrolled in the FOCUS study, randomized 2-to-1 so that 50 patients will receive UV1 and pembrolizumab and 25 patients will receive pembrolizumab alone. The primary endpoint of the study is the progression-free survival rate at 6 months. The first patient in the FOCUS trial was treated in August 2021. Top line data on the primary endpoint has been expected in H1 2024. Ultimovacs will review the guidance and expects to give an update with the Q4 2023 report.
Head and neck cancer is the term used to describe a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, and mouth. Globally, head and neck cancer accounts for 650,000 new cases of cancer and 330,000 deaths annually on average. In 2018, it was the seventh most common cancer worldwide with 890,000 new cases documented and 450,000 dying from the disease. The usual age at diagnosis is between 55 and 65 years old, and the average 5-year survival following diagnosis in the developed world is 42-64%.
LUNGVAC – non-small cell lung cancer (NSCLC)
The LUNGVAC trial is a multi-center, randomized, open-label, investigator-sponsored trial assessing the safety and efficacy of UV1 in combination with cemiplimab versus cemiplimab alone in NSCLC patients with advanced or metastatic disease. The trial will treat patients with tumors classified within the adenocarcinoma or squamous subgroups of NSCLC, where at least half of the tumor cells express the PD-L1 antigen and who have not previously received pembrolizumab treatment. These subgroups represent approximately 1/3 of all advanced and metastatic NSCLC patients. The primary endpoint of the trial will be progression-free survival. Secondary endpoints will include response rate and overall survival. The first patient was enrolled in October 2022, with topline readout expected by the second half of 2025. Ultimovacs will review the guidance and expects to give an update with the Q4 2023 report.
Professor Odd Terje Brustugun will be the principal investigator for the trial, which will be sponsored by Drammen Hospital, a leading oncology research center in Norway. The trial will enroll approximately 138 patients and will be conducted at 8-10 clinical centers in Norway.
Lung cancer is currently one of the most common cancers globally, and by far the biggest cause of cancer deaths in both men and women. NSCLC accounts for approximately 85% of all lung cancers. An estimated 850,000 new cases (in the US, EU5, Japan, China) of NSCLC are diagnosed each year. Most of these cases are metastatic patients, for whom the 5-year survival rate is around 7%.